- The FDA designates Auspex Pharmaceuticals' (ASPX +2.1%) investigational compound, SD-809, an Orphan Drug for the treatment of pediatric patients with Tourette syndrome. The product is currently in Phase 1b development.
- Among the benefits of Orphan Drug status is a seven-year period of market exclusivity if approved.